InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.340 0.02 (0.86%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3,035 Ceasing to be a substantial holder 22 Jul 2026 8:23AM $2.320 $2.340 risen by 0.86%
$3,035 Mesoblast CEO Makes Investment to Increase Share Ownership 21 Jul 2026 9:53AM $2.430 $2.340 fallen by 3.70%
$3,035 Appendix 3Y - Silviu Itescu 21 Jul 2026 9:47AM $2.430 $2.340 fallen by 3.70%
$3,035 Notification regarding unquoted securities - MSB 21 Jul 2026 9:43AM $2.430 $2.340 fallen by 3.70%
$3,035 Application for quotation of securities - MSB 21 Jul 2026 9:33AM $2.430 $2.340 fallen by 3.70%
$3,035 Notification of cessation of securities - MSB 14 Jul 2026 5:31PM $2.380 $2.340 fallen by 1.68%
$3,035 Notification regarding unquoted securities - MSB 14 Jul 2026 5:25PM $2.380 $2.340 fallen by 1.68%
$3,035 Application for quotation of securities - MSB 14 Jul 2026 5:21PM $2.380 $2.340 fallen by 1.68%
$3,035 Notification regarding unquoted securities - MSB 14 Jul 2026 5:15PM $2.380 $2.340 fallen by 1.68%
$3,035 Appendix 3Y - Silviu Itescu 14 Jul 2026 5:12PM $2.380 $2.340 fallen by 1.68%
$3,035 Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients 14 Jul 2026 10:00AM $2.320 $2.340 risen by 0.86%
$3,035 Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year 10 Jul 2026 9:57AM $2.100 $2.340 risen by 11.43%
$3,035 Receives FDA BLA Filing Number and Requests Modular Review 1 Jul 2026 9:56AM $1.955 $2.340 risen by 19.69%
$3,035 Becoming a substantial holder 30 Jun 2026 8:13AM $1.950 $2.340 risen by 20%
$3,035 Ceasing to be a substantial holder 29 Jun 2026 8:18AM $1.885 $2.340 risen by 24.14%
$3,035 Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility 25 Jun 2026 9:55AM $2.230 $2.340 risen by 4.93%
$3,035 Becoming a substantial holder 16 Jun 2026 8:18AM $1.955 $2.340 risen by 19.69%
$3,035 Ceasing to be a substantial holder 12 Jun 2026 8:23AM $1.970 $2.340 risen by 18.78%
$3,035 ASX CEO Connect Presentation 2 Jun 2026 11:51AM $2.025 $2.340 risen by 15.56%
$3,035 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 9:56AM $2.220 $2.340 risen by 5.41%
$3,035 Patient Recruitment Target Achieved in CLBP Pivotal Trial 29 Apr 2026 9:50AM $2.150 $2.340 risen by 8.84%
$3,035 Appendix 3Y for Gregory George 16 Apr 2026 5:22PM $2.240 $2.340 risen by 4.46%
$3,035 Notification of cessation of securities - MSB 16 Apr 2026 5:13PM $2.240 $2.340 risen by 4.46%
$3,035 Notification regarding unquoted securities - MSB 16 Apr 2026 5:09PM $2.240 $2.340 risen by 4.46%
$3,035 Application for quotation of securities - MSB 16 Apr 2026 5:05PM $2.240 $2.340 risen by 4.46%

1 - 25 of 1172 results

Page 1 of 47

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.